Find stats on top websites
Industry Landscape
The non-profit healthcare industry, particularly in disease-specific areas like Lyme disease, is characterized by a strong reliance on philanthropic funding and a focus on research, education, and patient support. It faces challenges in securing consistent funding and navigating complex medical controversies, while simultaneously striving to advance scientific understanding and improve patient outcomes through advocacy and awareness campaigns.
Total Assets Under Management (AUM)
Total charitable giving to health organizations in United States
~Not readily available as a specific number for Lyme disease non-profits; broader health giving metrics apply.
(Data not directly available for the sub-sector of Lyme disease non-profits. CAGR)
Growth in overall charitable giving to health has been modest.
Influenced by economic conditions and donor priorities.
Competition among non-profits for limited philanthropic dollars.
Total Addressable Market
Not directly applicable
Market Growth Stage
Pace of Market Growth
Emerging Technologies
AI-Powered Diagnostics
AI and machine learning can analyze complex patient data to improve the accuracy and speed of Lyme disease diagnosis, especially for challenging cases and co-infections.
CRISPR-based Research
CRISPR gene editing offers precision tools for understanding Lyme disease pathogenesis, developing new therapeutic targets, and potentially creating more effective treatments or vaccines.
Telehealth Platforms
Advanced telehealth solutions can expand access to Lyme-literate healthcare providers, facilitate remote monitoring, and improve patient support and education, especially in underserved areas.
Impactful Policy Frameworks
21st Century Cures Act (2016)
This bipartisan law accelerates the discovery, development, and delivery of 21st century cures, including provisions for increased medical research funding and streamlined regulatory processes for new therapies.
It encourages accelerated research and development for diseases like Lyme, potentially increasing funding opportunities and speeding up approval processes for new diagnostics and treatments, which can benefit GLA's research initiatives.
Tick-Borne Disease Act (2019/2021 Proposed)
While not a federal law yet, various iterations of a 'Tick-Borne Disease Act' have been proposed (e.g., as part of appropriations bills or standalone) aiming to increase federal funding for research, improve surveillance, and enhance public awareness for tick-borne diseases.
Passage of such an act would significantly increase dedicated federal funding for Lyme disease research and public health initiatives, providing substantial opportunities for organizations like GLA.
Changes to ICD-10-CM Codes for Tick-borne Diseases (Ongoing)
The International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes are updated periodically, which impacts how diseases, including tick-borne illnesses, are classified, tracked, and reimbursed by insurers.
Updates to these codes can influence how Lyme disease is recognized and reimbursed by insurance, potentially affecting patient access to care and funding for research and treatment, indirectly impacting GLA's patient advocacy efforts.
Transform Your Ideas into Action in Minutes with WaxWing
Sign up now and unleash the power of AI for your business growth
